HCT

Results: 265



#Item
211APS Quarterly Report Child Perf Measure Targeted Case Management (TCM) to a higher level of care Goal: At least 90% are NOT admitted to child inpatient or child PNMI or HCT within 6 months of discharge from TCM (Includes

APS Quarterly Report Child Perf Measure Targeted Case Management (TCM) to a higher level of care Goal: At least 90% are NOT admitted to child inpatient or child PNMI or HCT within 6 months of discharge from TCM (Includes

Add to Reading List

Source URL: www.maine.gov

Language: English - Date: 2014-05-14 13:54:30
212HCT Discharge Outcomes for Youth in Service 6 Months or More (Includes MaineCare members and Courtesy Reviews done by APS) Discharges between[removed]and[removed]and the new services authorized within 6 months of d

HCT Discharge Outcomes for Youth in Service 6 Months or More (Includes MaineCare members and Courtesy Reviews done by APS) Discharges between[removed]and[removed]and the new services authorized within 6 months of d

Add to Reading List

Source URL: www.maine.gov

Language: English - Date: 2014-05-05 12:43:41
213Micardis® HCT (telmisartan and hydrochlorothiazide) Tablets, 40 mg/12.5 mg 80 mg/12.5 mg and 80 mg/25 mg Rx only

Micardis® HCT (telmisartan and hydrochlorothiazide) Tablets, 40 mg/12.5 mg 80 mg/12.5 mg and 80 mg/25 mg Rx only

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-01-23 13:06:50
214After Action Reviews CERF Guidance CERF After-Action Guidance A CERF After Action Review (hereafter AAR) is a discussion that allows a Humanitarian Country Team (HCT) to reflect on the overall CERF process, how the HCT a

After Action Reviews CERF Guidance CERF After-Action Guidance A CERF After Action Review (hereafter AAR) is a discussion that allows a Humanitarian Country Team (HCT) to reflect on the overall CERF process, how the HCT a

Add to Reading List

Source URL: docs.unocha.org

Language: English - Date: 2014-05-28 08:41:53
215Guidance for Industry:  MedWatch Form FDA 3500A: Mandatory Reporting of Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

Guidance for Industry: MedWatch Form FDA 3500A: Mandatory Reporting of Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

Add to Reading List

Source URL: www.fda.gov

Language: English
216Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

Add to Reading List

Source URL: www.fda.gov

Language: English
217Guidance for Industry Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered From Donors

Guidance for Industry Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered From Donors

Add to Reading List

Source URL: www.fda.gov

Language: English
218-----------------------CONTRAINDICATIONS------------------------  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr

-----------------------CONTRAINDICATIONS------------------------ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-01-23 13:06:56
219-----------------WARNINGS AND PRECAUTIONS-----------------  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescribing

-----------------WARNINGS AND PRECAUTIONS----------------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescribing

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-06-07 09:40:04
220-----------------------CONTRAINDICATIONS------------------------  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr

-----------------------CONTRAINDICATIONS------------------------ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-02-17 16:53:43